VAXART

VXRT NASDAQ
0.6421
-0.0053
-0.82%
After Hours: 0.6500 +0.0079 +1.23% 16:41 08/16 EDT
Open
0.6500
Prev Close
0.6474
High
0.6500
Low
0.6340
Volume
45.60K
Avg Vol (3M)
143.87K
52 Week High
7.60
52 Week Low
0.5500
% Turnover
0.29%
Market Cap
10.14M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers VAXART VXRT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
MORE >

Recently

Name
Price
%Change